Spot on, the primary value would be to bundle up with a statin, offer as a single treatment. And yes, should have no probs with patenting that its a new treatment.
Secondary value as a stand alone treatment for those where a statin is ineffective. Could licence out right to use in conjunction with statin, and retain stand alone use development... a few options I suppose.
- Forums
- ASX - By Stock
- bull case
Spot on, the primary value would be to bundle up with a statin,...
Featured News
Add NYR (ASX) to my watchlist
|
|||||
Last
6.6¢ |
Change
0.007(11.9%) |
Mkt cap ! $12.02M |
Open | High | Low | Value | Volume |
5.9¢ | 6.6¢ | 5.8¢ | $32.64K | 541.6K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 48387 | 6.2¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
6.6¢ | 59999 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 48387 | 0.062 |
1 | 60000 | 0.058 |
3 | 36790 | 0.057 |
2 | 19357 | 0.056 |
2 | 133333 | 0.055 |
Price($) | Vol. | No. |
---|---|---|
0.066 | 59999 | 1 |
0.067 | 7000 | 1 |
0.068 | 50000 | 1 |
0.069 | 33333 | 1 |
0.070 | 3590 | 2 |
Last trade - 16.10pm 19/06/2024 (20 minute delay) ? |
Featured News
NYR (ASX) Chart |
The Watchlist
INF
INFINITY LITHIUM CORPORATION LIMITED
Ryan Parkin, Managing Director & CEO
Ryan Parkin
Managing Director & CEO
Previous Video
Next Video
SPONSORED BY The Market Online